Publications by authors named "Rowena Abbey"
Article Synopsis
- Lapatinib, an oral drug targeting EGFR and HER2, shows effectiveness as a single agent or with chemotherapy for metastatic breast cancer (MBC) that overexpresses HER2.
- A phase II trial evaluated lapatinib combined with paclitaxel in untreated HER2-overexpressing MBC patients, focusing on overall response rate (ORR) and other efficacy and safety measures.
- The results indicated a 51% ORR by independent review, with manageable side effects, suggesting the combination is a promising first-line treatment option for this patient group.
